NM_000384.3:c.10238delC
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000384.3(APOB):c.10238delC(p.Thr3413MetfsTer2) variant causes a frameshift change. The variant allele was found at a frequency of 0.0000167 in 1,613,968 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000384.3 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152198Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251264Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135812
GnomAD4 exome AF: 0.0000157 AC: 23AN: 1461770Hom.: 0 Cov.: 36 AF XY: 0.0000138 AC XY: 10AN XY: 727186
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152198Hom.: 0 Cov.: 33 AF XY: 0.0000269 AC XY: 2AN XY: 74362
ClinVar
Submissions by phenotype
Hypercholesterolemia, autosomal dominant, type B;C4551990:Familial hypobetalipoproteinemia 1 Pathogenic:2
- -
This sequence change creates a premature translational stop signal (p.Thr3413Metfs*2) in the APOB gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in APOB are known to be pathogenic (PMID: 20032471). This variant is present in population databases (rs756209187, gnomAD 0.002%). This premature translational stop signal has been observed in individual(s) with autosomal dominant hypobetalipoproteinemia (PMID: 1431583). This variant is also known as c.10366del. ClinVar contains an entry for this variant (Variation ID: 434252). For these reasons, this variant has been classified as Pathogenic. -
Hypobetalipoproteinemia Pathogenic:2
- -
This variant is also referred to as c.10366del in the literature. This frameshifting variant in exon 26 of 29 introduces a premature stop codon and is therefore predicted to result in loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay (NMD). This variant has been previously reported as a heterozygous change in patients with Hypobetalipoproteinemia (PMID: 1431583). Loss-of-function variation in APOB is an established mechanism of disease (PMID: 30939045). Experimental studies have shown that this c.10238del (p.Thr3413MetfsTer2) change results in decreased LDL-cholesterol levels and reduced APOB protein concentrations (PMID: 1431583). The c.10238del (p.Thr3413MetfsTer2) variant is present in the heterozygous state in the gnomAD population database at a frequency of 0.0007% (2/282662) and thus is presumed to be rare. Based on the available evidence, the c.10238del (p.Thr3413MetfsTer2) variant is classified as Pathogenic. -
Hypercholesterolemia, autosomal dominant, type B Pathogenic:1
The heterozygous c.10238del variant in APOB has previously been reported in individuals with associated familial hypercholesterolemia [PMID: 32719484] and it has been deposited in ClinVar (Var ID: 434252) as Pathogenic/Likely pathogenic. The c.10238del variant is observed in 7 alleles (~0.0011% minor allele frequency with 0 homozygotes) in population databases (gnomAD v2.1.1 and v3.1.2, TOPMed Freeze 8), suggesting it is not a common benign variant in the populations represented in those databases. The c.10238del variant in APOB is located in exon 26 of this 29-exon gene, predicted to incorporate a premature termination codon (p.(Thr3413MetfsTer2)), and is expected to result in loss-of-function via nonsense mediated decay. Multiple loss-of-function variants that are downstream to the c.10238del variant have been reported in ClinVar or literature in affected individuals. Based on available evidence this inherited c.10238del, p.(Thr3413MetfsTer2) variant identified in APOB is classified as Likely Pathogenic. -
APOB-related disorder Pathogenic:1
The APOB c.10238delC variant is predicted to result in a frameshift and premature protein termination (p.Thr3413Metfs*2). This variant has been reported to segregate with disease in a three-generation family with hypobetalipoproteinemia (Krul et al. 1992. PubMed ID: 1431583). It has also been reported in individuals with nonalcoholic fatty liver disease (Vilar-Gomez et al. 2021. PubMed ID: 33454241). This variant is reported in 0.0016% of alleles in individuals of European (non-Finnish) descent in gnomAD. Frameshift variants in APOB are expected to be pathogenic and this variant has been interpreted as pathogenic and likely pathogenic by other laboratories in the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/variation/434252/). This variant is interpreted as pathogenic. -
not provided Pathogenic:1
- -
Familial hypobetalipoproteinemia 1 Pathogenic:1
The p.Thr3413Metfs variant in APOB has not been previously reported in individuals with low LDL but has been identified in in 0.00155% (2/129014) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs756209187). This variant has also been reported in ClinVar (VariationID: 434252) as pathogenic by the University of Chicago. This variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at position 3413 and leads to a premature termination codon 2 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the APOB gene is an established disease mechanism in autosomal recessive low LDL. In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic. ACMG/AMP Criteria applied: PM2, PVS1 (Richards 2015). -
Cardiovascular phenotype Pathogenic:1
The c.10238delC pathogenic mutation, located in coding exon 26 of the APOB gene, results from a deletion of one nucleotide at nucleotide position 10238, causing a translational frameshift with a predicted alternate stop codon (p.T3413Mfs*2). This variant has been detected in the heterozygous state in individuals with low LDL cholesterol, some of whom also had fatty liver disease (Krul ES et al. J Lipid Res. 1992 Jul;33(7):1037-50; Vilar-Gomez E et al. J Clin Lipidol. 2021 Dec;15(2):275-291). One study reported this variant to result in increased LDL receptor binding (Krul ES et al. J Lipid Res. 1992 Jul;33(7):1037-50). Although biallelic loss of function alterations in APOB have been associated with autosomal recessive hypobetalipoproteinemia, haploinsufficiency for APOB has not been clearly established as a mechanism of disease for autosomal dominant familial hypercholesterolemia. Based on the supporting evidence, this variant would be expected to cause autosomal recessive hypobetalipoproteinemia when present along with a second pathogenic or likely pathogenic variant on the other allele; however, the association of this alteration with autosomal dominant familial hypercholesterolemia is unlikely. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at